Pharma.Aero Welcomes Pharmaceutical Heavyweights to LMAP
Alexion – AstraZeneca Rare Disease, GSK, Novartis, Pfrizer, and Zoetis will join the newly established life sciences platform.
Pharma.Aero is expanding its global network of life sciences and med tech manufacturers, welcoming Alexion – AstraZeneca Rare Disease, GSK, and Novartis, along with MSD, Pfizer, and Zoetis, to the recently created life sciences manufacturers advisory platform (LMAP).
The organization will further engage the manufacturing segment to offer advice on the activities and projects of Pharma.Aero and create a cluster of life sciences and med tech companies to support the logistics and supply chain industry. The LMAP is expected to integrate into all Pharma.Aero cross-industry initiatives.
“We create the life sciences manufacturers advisory platform (LMAP) as a dedicated collaborative eco-system that will provide invaluable guidance and expertise to shape the activities and projects undertaken by Pharma.Aero,” says Trevor Caswell, Pharma.Aero chairman. “By leveraging the collective knowledge and experience of our advisory members, we will strengthen our organization's value proposition and provide enhanced content that delivers tangible benefits and shapes the future of the life sciences logistics and supply chain industry.”
